Elias Orouji

Elias Orouji

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell Reports
Verified
Journal Article
Open access
MMMayinuer Maitituoheti
Mayinuer Maitituoheti
EKEmily Z. Keung
Emily Z. Keung
MTMing Tang
Ming Tang
LYLiang Yan
Liang Yan
HAHunain Alam
Hunain Alam
KRKunal Rai
Kunal Rai
Histone methyltransferase KMT2D harbors frequent loss-of-function somatic point mutations in several tumor types, including melanoma. Here, we identify KMT2D as a potent tumor suppressor in melanoma through an in vivo epigenome-focused pooled RNAi screen and confirm the finding by using a genetically engineered mouse model (GEMM) based on conditional and melanocyte-specific deletion of KMT2D. KMT2D-deficient tumors show substantial reprogramming of key metabolic pathways, including glycolysis. KMT2D deficiency aberrantly upregulates glycolysis enzymes, intermediate metabolites, and glucose consumption rates. Mechanistically, KMT2D loss causes genome-wide reduction of H3K4me1-marked active enhancer chromatin states. Enhancer loss and subsequent repression of IGFBP5 activates IGF1R-AKT to increase glycolysis in KMT2D-deficient cells. Pharmacological inhibition of glycolysis and insulin growth factor (IGF) signaling reduce proliferation and tumorigenesis preferentially in KMT2D-deficient cells. We conclude that KMT2D loss promotes tumorigenesis by facilitating an increased use of the glycolysis pathway for enhanced biomass needs via enhancer reprogramming, thus presenting an opportunity for therapeutic intervention through glycolysis or IGF pathway inhibitors.

31 May 2021 in Gut
Verified
Journal Article
Closed access
PDF file
EOElias Orouji
Elias Orouji
ARAyush Raman
Ayush Raman
ASAnand K Singh
Anand K Singh
ASAlexey Sorokin
Alexey Sorokin
EAEmre Arslan
Emre Arslan
KRKunal Rai
Kunal Rai
Objective: Enhancer aberrations are beginning to emerge as a key epigenetic feature of colorectal cancers (CRC), however, a comprehensive knowledge of chromatin state patterns in tumour progression, heterogeneity of these patterns and imparted therapeutic opportunities remain poorly described. Design: We performed comprehensive epigenomic characterisation by mapping 222 chromatin profiles from 69 samples (33 colorectal adenocarcinomas, 4 adenomas, 21 matched normal tissues and 11 colon cancer cell lines) for six histone modification marks: H3K4me3 for Pol II-bound and CpG-rich promoters, H3K4me1 for poised enhancers, H3K27ac for enhancers and transcriptionally active promoters, H3K79me2 for transcribed regions, H3K27me3 for polycomb repressed regions and H3K9me3 for heterochromatin. Results: We demonstrate that H3K27ac-marked active enhancer state could distinguish between different stages of CRC progression. By epigenomic editing, we present evidence that gains of tumour-specific enhancers for crucial oncogenes, such as ASCL2 and FZD10, was required for excessive proliferation. Consistently, combination of MEK plus bromodomain inhibition was found to have synergistic effects in CRC patient-derived xenograft models. Probing intertumour heterogeneity, we identified four distinct enhancer subtypes (EPIgenome-based Classification, EpiC), three of which correlate well with previously defined transcriptomic subtypes (consensus molecular subtypes, CMSs). Importantly, CMS2 can be divided into two EpiC subgroups with significant survival differences. Leveraging such correlation, we devised a combinatorial therapeutic strategy of enhancer-blocking bromodomain inhibitors with pathway-specific inhibitors (PARPi, EGFRi, TGFβi, mTORi and SRCi) for EpiC groups. Conclusion: Our data suggest that the dynamics of active enhancer underlies CRC progression and the patient-specific enhancer patterns can be leveraged for precision combination therapy.

1 June 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
RSRashim Pal Singh
Rashim Pal Singh
DJDanny V. Jeyaraju
Danny V. Jeyaraju
VVVeronique Voisin
Veronique Voisin
RHRose Hurren
Rose Hurren
CXChangjiang Xu
Changjiang Xu
ASAaron Schimmer
Aaron Schimmer

20 April 2015 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
SOShaida Ouladan
Shaida Ouladan
MTMarcel Trautmann
Marcel Trautmann
EOElias Orouji
Elias Orouji
WHWolfgang Hartmann
Wolfgang Hartmann
SHSebastian Huss
Sebastian Huss
EWEva Wardelmann
Eva Wardelmann
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms, displaying variable morphological and clinicopathological features. Supportive immunohistochemical markers such as CD34, CD99, BCL2 and LSD1 are commonly applied in the differential diagnosis of SFTs, although none is sufficiently sensitive or specific enough. The aim of the present study was to examine the most differential markers for the reliable distinction of SFTs from histological mimics. We investigated the expression of STAT6, NAB2, ALDH1, GRIA2 and IGF2 in 454 comprehensive soft tissue tumors, comprising formalin-fixed paraffin-embedded (FFPE) tissue samples from 80 SFTs and 374 other mesenchymal tumors. The Duolink in situ proximity ligation assay (PLA) was adopted for the detection of NAB2-STAT6 fusion proteins. STAT6 was expressed in all 80 SFT cases with a moderate-strong nuclear staining intensity. In contrast, only 4/374 (1%) non-SFT mesenchymal tumors showed a nuclear STAT6 staining pattern. Strong expression of NAB2 and IGF2 was detected in SFT and non-SFT cases. Positive GRIA2 immunoreactivity was found in 64% (SFT) and 8% (non-SFT), respectively. Expression of ALDH1 was moderate-strong in 76% (SFT), whereas only 2 non-SFT lesions showed positive ALDH1 immunoreactivity. Moreover, the presence of NAB2‑STAT6 fusion proteins was indicated in 71/78 (91%) SFT cases by PLA. Nuclear STAT6 and cytoplasmic ALDH1 expression are the most sensitive and specific markers in the differential diagnosis of SFTs. Furthermore, application of Duolink in situ proximity ligation assay can be helpful to detect the NAB2-STAT6 fusion protein in the majority of SFTs.

22 April 2015 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
LLLionel Larribère
Lionel Larribère
HWHuizi Wu
Huizi Wu
DNDaniel Novak
Daniel Novak
MGMarta Galach
Marta Galach
MBMathias Bernhardt
Mathias Bernhardt
Jochen UtikalJochen Utikal
Jochen Utikal

27 May 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
EOElias Orouji
Elias Orouji
AFAniello Federico
Aniello Federico
LLLionel Larribère
Lionel Larribère
DNDaniel Novak
Daniel Novak
DLDaniel B. Lipka
Daniel B. Lipka
Jochen UtikalJochen Utikal
Jochen Utikal